Candel Therapeutics, Inc. (CADL)

Candel Therapeutics Inc (NASDAQ:CADL) CEO talked with Proactive earlier this week about the company's recent achievements in oncology drug development, with a strong focus on its gene therapy programs. CEP Dr Paul Peter Tak said Candel has had “another very successful quarter”, highlighting that its lead program CAN-2409 achieved its primary endpoint in early localized, newly diagnosed prostate cancer.

Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it plans to seek US approval for its lead cancer drug CAN-2409 in late 2026, after a key Phase 3 prostate cancer trial succeeded and the FDA granted it Regenerative Medicine Advanced Therapy (RMAT) status. The clinical-stage biotech reported a narrower second-quarter loss, backed by stronger trial results and financing that will help support launch readiness activities.

NEEDHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the second quarter ended June 30, 2025, and provided a corporate update.

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference, being held on August 12-14, 2025 in Boston, MA.

Candel Therapeutics Inc (NASDAQ:CADL) announced that the European Medicines Agency (EMA) has granted Orphan Designation to its investigational immunotherapy CAN-2409 for the treatment of pancreatic cancer. The designation adds to CAN-2409's existing Orphan Drug Designation and Fast Track Designation from the US Food and Drug Administration for pancreatic ductal adenocarcinoma.

NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This designation complements CAN-2409's existing U.S. Food and Drug Administration (FDA) Orphan Drug Designation and FDA Fast Track Designation for the treatment of pancreatic ductal adenocarcinoma (PDAC) awarded to CAN-2409 in April 2024 and December 2023, respectively, and underscores the significant unmet medical need in this disease beyond the U.S.

Candel Therapeutics Inc (NASDAQ:CADL) has announced its inclusion in several value-oriented Russell indexes as part of the 2025 Russell US Indexes annual reconstitution. The changes became effective with the opening of the US markets on June 30.

NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company was added to multiple Russell indexes as part of the 2025 Russell US Indexes annual reconstitution, which became effective at the open of the U.S. equity markets on June 30, 2025.

Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Candel Therapeutics Inc (NASDAQ:CADL) has announced a $15 million registered direct offering of common stock, the proceeds of which will support launch readiness, medical affairs, and pre-commercialization activities, as well as preparation for a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer, expected in the fourth quarter of 2026. “We are pleased to strengthen our financial position with the resources intended to support pre-commercialization and launch readiness activities for CAN-2409 in prostate cancer, pending regulatory approval, as well as other key corporate purposes,” Candel CEO Dr Paul Peter Tak said.

NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has agreed to sell approximately 3.2 million shares of its common stock (Common Stock) to a select group of accredited investors in a registered direct offering (the Offering), at a price per share of $4.67. The Offering is expected to close on June 25, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting offering-related expenses payable by the Company.

Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Charles Schoch as its chief financial officer. Schoch had served as interim CFO since January 2024 and is being elevated to the permanent position following a key period of operational and financial execution, the company said on Monday.

Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones

Candel Therapeutics Inc (NASDAQ:CADL) has appointed biotechnology industry veteran Maha Radhakrishnan, M.D., to its board of directors.

Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development

The average of price targets set by Wall Street analysts indicates a potential upside of 285.3% in Candel Therapeutics (CADL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.